Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medic...(via(TM) in Asia. About Raptor Ph...),Health

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it believes it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("Huntington's"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Dr. Rioux' successful clinical and regulatory track record will benefit and / or advance the Company's clinical-stage programs through the clinic and into the market; that the Company's pipeline could address serious unmet medical needs; that the Company will be successful in initiating and / or completing its planned clinical trials; that the Company will successfully file an NDA in 2010; that clinical results from planned or ongoing clinical trials will be available as planned or that th
'/>"/>